NEW YORK--(BUSINESS WIRE)--Bioenvision, Inc. (Nasdaq: BIVN) announced today that it has received an aggregate of $7.4 million as a result of the exercise by existing company investors of previously issued warrants. Perseus-Soros Biopharmaceutical Fund, L.P. exercised warrants to purchase 3,000,000 shares of Bioenvision common stock at a purchase price of $2.00 per share and SCO Capital and its affiliates exercised warrants to purchase an aggregate of 938,333 shares of our common stock at a purchase price of $1.50 per share. The warrants were issued originally in a private placement of common stock and warrants in May 2002 and have been exercisable since that date. The warrants would have expired on May 7, 2007 if not exercised. As a result of the exercise of the warrants, Bioenvision received net cash proceeds of $7.4 million.
